Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
Mehdi Sekssaoui, Joël Bockaert, Philippe Marin, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 4, pp. 747-756
Open Access | Times Cited: 22

Showing 22 citing articles:

Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications
Francesco Weiss, Anna Magnesa, Matteo Gambini, et al.
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 117-117
Open Access | Times Cited: 4
Psychedelic therapy in depression and substance use disorders
Nur Damla Korkmaz, Uğur Çıkrıkçılı, Merve Akan, et al.
European Journal of Neuroscience (2024) Vol. 60, Iss. 2, pp. 4063-4077
Open Access | Times Cited: 10
Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats
Zitong Wang, Brett Robbins, R. L. Zhuang, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111243-111243
Open Access
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
I. Erkizia-Santamaría, Igor Horrillo, J. Javier Meana, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111249-111249
Closed Access
Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers
Juliana Lima Constantino, Jens H. van Dalfsen, Sara Massetti, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 136, pp. 111251-111251
Open Access
Mice Lacking the Serotonin Transporter do not Respond to the Behavioural Effects of Psilocybin
James J Gattuso, Carey Wilson, Shanshan Li, et al.
European Journal of Pharmacology (2025), pp. 177304-177304
Closed Access
Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives
Sung‐Hyun Kim, Sumin Yang, Jeehye Jung, et al.
Advanced Science (2025)
Open Access
Structural basis for psilocybin biosynthesis
Chunyan Meng, Wenting Guo, Xiao Chuan, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Serotonergic neuromodulation of synaptic plasticity
Guilherme Shigueto Vilar Higa, Felipe José Costa Viana, José Fernando de Oliveira, et al.
Neuropharmacology (2024) Vol. 257, pp. 110036-110036
Closed Access | Times Cited: 3
Rethinking the role of TRKB in the action of antidepressants and psychedelics
Cecilia A. Brunello, Cecilia Cannarozzo, Eero Ċastrén
Trends in Neurosciences (2024)
Open Access | Times Cited: 3
Patient-derived induced pluripotent stem cells: Tools to advance the understanding and drug discovery in Major Depressive Disorder
Andreia Vaz, António J. Salgado, Patrícia Patrício, et al.
Psychiatry Research (2024) Vol. 339, pp. 116033-116033
Open Access | Times Cited: 2
Psychedelic 25H-NBOMe attenuates post-sepsis depression in rats
B. Ferri, Cíntia O. de Novais, Viviana Carolina Trujillo Rojas, et al.
Neuroscience Letters (2024) Vol. 834, pp. 137845-137845
Closed Access | Times Cited: 1
Biological Sex Modulates the Efficacy of 2,5-dimethoxy-4-iodoamphetamine (DOI) to Mitigate Fentanyl Demand
Alice J McQueney, Erik J. Garcia
Drug and Alcohol Dependence (2024) Vol. 263, pp. 112426-112426
Closed Access | Times Cited: 1
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents
Isabel Werle, Leandro J. Bertoglio
Neuroscience & Biobehavioral Reviews (2024), pp. 105899-105899
Closed Access | Times Cited: 1
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
Laith Alexander, David J. Anderson, Luke Baxter, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
Daniël Hoyer
Authorea (Authorea) (2024)
Open Access
Psychiatric Applications of Psychedelics
Praachi Tiwari, Rebecca Ehrenkranz, David B. Yaden
Advances in Psychiatry and Behavioral Health (2024) Vol. 4, Iss. 1, pp. 47-56
Closed Access
Pyramidal cell types and 5-HT2A receptors are essential for psilocybin's lasting drug action
Ling-Xiao Shao, Clara Liao, Pasha A. Davoudian, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Dimethyltryptamine (DMT) and ibogaine elicit membrane effects in HEK cells transiently transfected with the human 5-HT2A receptor
Jannik Nicklas Eliasen, Uffe Kristiansen, Kristi A. Kohlmeier
Brain Research (2024), pp. 149425-149425
Closed Access
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Moritz Spangemacher, Lea J. Mertens, Luca Valentino Färber, et al.
Deutsches Ärzteblatt international (2024)
Closed Access
The psychoplastogens ibogaminalog and ibogainalog induce antidepressant-like activity in naïve and depressed mice by mechanisms involving 5-HT2A receptor activation and serotonergic transmission
Hugo R. Arias, Deborah Rudin, Dino Luethi, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 136, pp. 111217-111217
Closed Access
Page 1

Scroll to top